Aulos BioscienceAulos Bioscience
  • Our Approach
    • Overview
    • Platform
    • Abstracts and Publications
  • Our Pipeline
    • Overview
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Investors
    • Corporate Presentation
    • Mission and Values
  • Newsroom
    • Latest News
    • Media Inquiries
  • Careers
    • Join the team
  • Contact
    • General Inquiries
Search
  • Our Approach
    • Overview
    • Platform
    • Abstracts and Publications
  • Our Pipeline
    • Overview
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Investors
    • Corporate Presentation
    • Mission and Values
  • Newsroom
    • Latest News
    • Media Inquiries
  • Careers
    • Join the team
  • Contact
    • General Inquiries
Slide

Newsroom

  • Latest News
  • Media Inquiries

Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer

LARKSPUR, CALIFORNIA, June 14, 2021/PRNewswire/ — Aulos Bioscience, a biotechnology company developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, has appointed Jim Vasselli, M.D. as the company’s chief medical officer, effective today. In this new role, Dr. Vasselli will lead the design for the AU-007 clinical development plan including regulatory strategy, protocol development, operational execution of clinical trials, and management of relationships with key opinion leaders and trial investigators. In addition, he will be a member of the Aulos executive team with responsibility for aligning clinical strategy with the company’s overall clinical development plans.

“Jim is a fantastic addition to the Aulos leadership team,” said Aulos Bioscience chief executive officer Aron Knickerbocker. “His deep expertise and successful record in cancer clinical trial design and conduct, his strategic vision, and his ability to synthesize scientific, regulatory, and patient perspectives will provide strong support as we advance our lead candidate AU-007 into the clinic later this year.”

Dr. Vasselli brings to Aulos extensive knowledge and proficiency gained through more than 25 years leading oncology research and development projects across a broad array of tumor types and therapeutic modalities. Most recently, as senior vice president of Clinical Development at Maverick Therapeutics (acquired by Takeda in April 2021), he progressed a conditionally active CD3 x EGFR bispecific molecule from preclinical studies to a first-in-human clinical trial. Prior to that, Dr. Vasselli served as vice president of Clinical Research for MacroGenics, developing clinical strategy and overseeing execution of phase 1 and 2 studies for multiple immuno-oncology assets including CD3-engaging bispecifics, monoclonal antibodies, and ADC compounds. He also spent nine years at AstraZeneca / MedImmune leading early clinical development of the anti-PD-L1 drug durvalumab and pivotal trials of the kinase inhibitor vandetanib. Dr. Vasselli began his career in academic research with 10 years at the National Institutes of Health (NIH)’s National Cancer Institute (NCI), in a surgical oncology fellowship evaluating IL-2 in patients with kidney cancer and melanoma and as a Basic Science Research Fellow in the NCI Urology branch. He holds a B.A. in engineering from Lafayette College and an M.D. from New York Medical College; he completed a general surgical residency at Morristown Memorial Hospital.

Dr. Vasselli commented, “I’m excited to join the innovative team at Aulos. Having administered high-dose IL-2 to cancer patients early in my career, I have seen its potential to deliver substantial efficacy – and also its potential toxicity and very narrow therapeutic index. I am impressed by Aulos’ elegant approach, which seeks to widen IL-2’s therapeutic index to both enhance its immune-stimulating and anti-tumor properties and reduce its suppressive effects and toxicity, and which avoids the technical complexities of other approaches in this competitive field. I look forward to working with my new colleagues to move AU-007 into human trials, in which we aim to reveal the full potential of IL-2 to improve the lives of people with cancer.”

About Aulos Bioscience
Aulos Bioscience, an ATP company, is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics. Aulos is initially developing unique IL-2 targeting antibodies that it believes have the potential to become best-in-class treatments for solid tumors. The company’s lead candidate is AU-007, a computationally designed, fully human antibody that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, AU-007 reinforces anti-tumor immune effects at the site of endogenous IL-2 release by preventing the negative feedback to T regulatory cells, biasing towards immune activation over suppression. For more information, visit www.aulosbio.com.

Contact: info@aulosbio.com
Media inquiries: Mike Beyer, Sam Brown Inc. / 312-961-2502 / mikebeyer@sambrown.com

Aulos Bio favicon-32x32

AULOS BIOSCIENCE
700 LARKSPUR LANDING CIRCLE
SUITE 108
LARKSPUR, CA 94939

LinkedIn
twitter
  • Our Approach
  • Overview
  • Platform
  • Abstracts and Publications
  • Our Pipeline
  • Overview
  • About Us
  • Overview
  • Leadership
  • Board of Directors
  • Investors
  • Corporate Presentation
  • Mission and Values
  • Newsroom
  • Latest News
  • Media Inquiries
  • Careers
  • Join the team
  • Contact
  • General Inquiries
  • Terms of Use
  • Privacy
  • Social Media
  • CA Compliance
© Copyright 2023. All Rights Reserved.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT